Trimethylammonium

Trimethylammonium

SCHEMBL895151

C=C(C)C(=O)NCC.CN(C)C.CN(C)C.Cl

nearest known ligand 0.39

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Trimethylammonium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP1 known ✓ P03956 1/20 0.33
MMP8 known ✓ P22894 1/20 0.33
CHRNB4 known ✓ P30926 1/20 0.32
CHRNA3 known ✓ P32297 1/20 0.32
GAA known ✓ P10253 1/20 0.31
TGFBR1 P36897 1/20 0.39
PLAAT3 P53816 1/20 0.33
PLAAT5 Q96KN8 1/20 0.33
PLAAT2 Q9NWW9 1/20 0.33
PLAAT4 Q9UL19 1/20 0.33
MMP2 P08253 1/20 0.33
MMP3 P08254 1/20 0.33
MMP9 P14780 1/20 0.33
THRB P10828 1/20 0.32
KMT2A Q03164 1/20 0.32
ALDH1A1 P00352 3/20 0.32
CHRNB2 P17787 1/20 0.32
CHRNA4 P43681 1/20 0.32
MCL1 Q07820 1/20 0.31
TDP1 Q9NUW8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trimethylammonium SCHEMBL869214 1.00 TGFBR1 (0.39) TGFBR1PLAAT3PLAAT5PLAAT2PLAAT4
Trimethylammonium SCHEMBL444000 0.98 TGFBR1 (0.41) TGFBR1PLAAT3PLAAT5PLAAT2PLAAT4
Trimethylammonium SCHEMBL176133 0.95 TGFBR1 (0.39) TGFBR1PLAAT3PLAAT5PLAAT2PLAAT4
Trimethylammonium SCHEMBL28049014 0.95 TGFBR1 (0.39) TGFBR1PLAAT3PLAAT5PLAAT2PLAAT4
Hydrochloric Acid SCHEMBL15846120 0.93
N,N-Dimethylethanaminium SCHEMBL7057093 0.91 TGFBR1 (0.37) TGFBR1PLAAT3PLAAT5PLAAT2PLAAT4
Hydrochloric Acid SCHEMBL6561920 0.91 TGFBR1 (0.42) TGFBR1PLAAT3PLAAT5PLAAT2PLAAT4
SCHEMBL14949 0.91
N,N-Dimethylethanaminium SCHEMBL446422 0.89 TGFBR1 (0.38) TGFBR1PLAAT3PLAAT5PLAAT2PLAAT4
Dimethylamine SCHEMBL8512095 0.88 TGFBR1 (0.41) TGFBR1PLAAT3PLAAT5PLAAT2PLAAT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2579972-A1 METHOD FOR PREPARING A NON-IONIC SURFACTANT STABLE PERSONAL CARE DISPERSION The Procter and Gamble Company (US) 2013-04-17 EP claimed
EP-1976888-B1 PROCESS FOR PREPARING A COPOLYMER WITH CONTROLLED ARCHITECTURE, OF TELOMER OR BLOCK COPOLYMER TYPE, OBTAINED FROM VINYL PHOSPHONATE MONOMERS, BY IODINE TRANSFER POLYMERIZATION RHODIA OPERATIONS (FR) 2012-06-13 EP claimed
US-7737237-B2 Controlled structure copolymer comprising an amphoteric or zwitterionic part PHODIA CHIMIE (FR) 2010-06-15 US claimed
US-20090087398-A1 Method for Treating Damaged Hair THE PROCTER & GAMBLE COMPANY 2009-04-02 US claimed
US-20090053165-A1 Method for Treating Damaged Hair THE PROCTER & GAMBLE COMPANY 2009-02-26 US claimed
US-7473730-B2 Method for depositing a polymer onto a surface by applying a composition onto said surface RHODIA CHIMIE (FR) 2009-01-06 US claimed
US-20080206355-A1 Composition comprising a particulate zinc material, a pyrithione or a polyvalent metal salt of a pyrithione and a synthetic cationic polymer THE PROCTER & GAMBLE COMPANY 2008-08-28 US claimed
US-20060217285-A1 Controlled structure copolymer comprising an amphoteric or zwitterionic part RHODIA CHIMIE (FR) 2006-09-28 US claimed
US-20050180937-A1 Method for depositing a polymer onto a surface by applying a composition onto said surface CADENA NATALIE (US) 2005-08-18 US claimed
US-20210315791-A1 SHAMPOO COMPOSITION WITH NON-SULFATE SURFACTANT AND COMPLEXATION COMPOUND FORMING A COACERVATE WELLA INTERNATIONAL OPERATIONS SWITZERLAND SÀRL (CH) 2021-10-14 US disclosed
US-10912719-B2 Personal care composition and method of making THE PROCTER AND GAMBLE COMPANY (US) 2021-02-09 US disclosed
WO-2020030732-A1 SHAMPOO COMPOSITION WITH NON-SULFATE SURFACTANT AND COMPLEXATION COMPOUND FORMING A COACERVATE HFC PRESTIGE INTERNATIONAL HOLDING SWITZERLAND S.A.R.L (CH) 2020-02-13 WO disclosed
US-20160106663-A1 PERSONAL CARE COMPOSITION AND METHOD OF MAKING THE PROCTER & GAMBLE COMPANY 2016-04-21 US disclosed
US-20160095809-A1 METHOD OF IMPROVED VOLUME AND COMBABILITY USING PERSONAL CARE COMPOSITION COMPRISING A PRE-EMULSIFIED FORMULATION THE PROCTER & GAMBLE COMPANY 2016-04-07 US disclosed
US-20060234901-A1 Polymer-fluorosurfactant associative complexes CLOROX COMPANY, THE 2006-10-19 US disclosed
US-20050245650-A1 Method for preparing an emulsion by diluting an emulsifiable concentrate comprising an amphiphilic copolymer RHODIA CHIMIE (FR) 2005-11-03 US disclosed
US-20050203256-A1 Poymer obtained by means of controlled radical polymerisation comprising at least one boronate function, association thereof with a ligand compound and uses of same RHODIA CHIMIE (FR) 2005-09-15 US disclosed
US-20050181225-A1 Use of block copolymers bearing phosphate and/or phosphonate functions as adhesion promoters or as protecting agents against the corrosion of a metallic surface CHIMIE, RHODIA (FR) 2005-08-18 US disclosed
US-20050176863-A1 Rare earth aggregate formulation using di-block copolmers RHODIA INC. 2005-08-11 US disclosed
WO-2003035791-A1 COMPOSITION FOR AVOIDING OR REDUCING THE BUILD-UP OF ICE AND SNOW, METHOD FOR PRODUCTION AND USE OF SAID COMPOSITION BASF AKTIENGESELLSCHAFT (DE) 2003-05-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10912719-B2 Personal care composition and method of making CUTA, POLR1C, KRT18 MMP1 1648/4885MMP8 2785/4885CHRNB4 4509/4885
US-20080206355-A1 Composition comprising a particulate zinc material, a pyrithione or a polyvalent metal salt of a pyrithione and a synthetic cationic polymer SLC39A3, SLC39A14, SLC30A7 MMP1 3740/4885MMP8 4265/4885CHRNB4 862/4885
US-20090053165-A1 Method for Treating Damaged Hair PLOD3, CUTA, SGMS2 MMP1 337/4885MMP8 1330/4885CHRNB4 4416/4885
US-20160095809-A1 METHOD OF IMPROVED VOLUME AND COMBABILITY USING PERSONAL CARE COMPOSITION COMPRISING A PRE-EMULSIFIED FORMULATION POLR1C, SGMS1, CERT1 MMP1 71/4885MMP8 216/4885CHRNB4 4228/4885
US-20090087398-A1 Method for Treating Damaged Hair LPO, MAG, CUTA MMP1 922/4885MMP8 1503/4885CHRNB4 4379/4885
US-20210315791-A1 SHAMPOO COMPOSITION WITH NON-SULFATE SURFACTANT AND COMPLEXATION COMPOUND FORMING A COACERVATE PSAP, SPAST, SYMPK MMP1 930/4885MMP8 1279/4885CHRNB4 3249/4885
US-20160106663-A1 PERSONAL CARE COMPOSITION AND METHOD OF MAKING CUTA, POLR1C, KRT18 MMP1 1648/4885MMP8 2785/4885CHRNB4 4509/4885
US-20050180937-A1 Method for depositing a polymer onto a surface by applying a composition onto said surface C5, ITGB5, MMAB MMP1 1366/4885MMP8 3192/4885CHRNB4 75/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.